Genes encoding components of the TGFbl signaling pathway including TGFB1 and TGFBRI are functionally polymorphic in humans, and carrier status of specific variants determines human cancer risk. However, TGFbl has pleiotropic activity on many different cell types, and can have both positive and negative effects on tumorigenesis, thus different human genetic association studies have often resulted in divergent conclusions. In a mouse model of skin tumorigenesis, it has been shown that tumor susceptibility associated with a hyperactive Tgfbl allele is dependent on genetic interaction of the Tgfbl gene with an unlinked variant skin tumor susceptibility locus, SktslS. Genetic linkage analysis of TGFbl knock out mice had previously independently identified the Skts15 region as a Tgfbl-interacting locus, TgfbmS. The overall goal of this project is to determine the biological and molecular mechanisms whereby Tgfbl and Skts15/Tgfbm3 interact to determine cancer susceptibility in mice, and to elucidate whether similar genetic interactions between TGFB1 and TGFBM3/SKTS15 alter cancer risk in humans. A panel of NIH mice, congenic for C57 (or spretus) at the Skts15/Tgfbm3 locus, will be used to validate and finely map Skts15/Tgfbm3 for identification of tumor susceptiblity genes, and to investigate the biological parameters that contribute to this altered tumor susceptibility. Parameters will include growth and apoptosis effects on the tumor cell and host tissues, inflammation, immune surveillance and tumor angiogenesis. A human genetic association study will be performed in a large case control study of women with breast cancer, focusing on genes within SKTS15/TGFBM3 and their potential interaction with TGFB1, and other key TGFbeta signaling components. The importance of TGFbl signaling to cancer progression and spread is reflected by the commencement of clinical trials of TGFb pathway inhibitors for treatment of metastatic cancers. Yet much still remains to be learnt about the precise biological and molecular pathways involved in TGFbl-mediated tumor progression;essential information to the refined development of these new drugs. The information gained from this project: a) Will add to knowledge on the biological and molecular pathways of TGFbl-mediated tumor progression, b) May contribute to screening tools for assessment of cancer risk in humans c) May provide new targets or indicate certain combinatorial targets for anti-cancer drug development d) May contribute to design of personalized medicines for anti-TGFbeta cancer therapies

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA116019-04
Application #
7755814
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Okano, Paul
Project Start
2007-05-01
Project End
2012-01-31
Budget Start
2010-02-01
Budget End
2012-01-31
Support Year
4
Fiscal Year
2010
Total Cost
$292,084
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Kawasaki, Kyoko; Freimuth, Julia; Meyer, Dominique S et al. (2014) Genetic variants of Adam17 differentially regulate TGF? signaling to modify vascular pathology in mice and humans. Proc Natl Acad Sci U S A 111:7723-8
Benzinou, Michael; Clermont, Frederic F; Letteboer, Tom G W et al. (2012) Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nat Commun 3:616
Connolly, Erin C; Freimuth, Julia; Akhurst, Rosemary J (2012) Complexities of TGF-? targeted cancer therapy. Int J Biol Sci 8:964-78
Lamouille, Samy; Connolly, Erin; Smyth, James W et al. (2012) TGF-?-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci 125:1259-73
Akhurst, Rosemary J; Hata, Akiko (2012) Targeting the TGF? signalling pathway in disease. Nat Rev Drug Discov 11:790-811
Connolly, Erin C; Saunier, Elise F; Quigley, David et al. (2011) Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term T?RI/II kinase inhibition with LY2109761. Cancer Res 71:2339-49
Connolly, Erin C; Akhurst, Rosemary J (2011) The complexities of TGF-? action during mammary and squamous cell carcinogenesis. Curr Pharm Biotechnol 12:2138-49
Bouquet, Fanny; Pal, Anupama; Pilones, Karsten A et al. (2011) TGFýý1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res 17:6754-65
Barcellos-Hoff, Mary Helen; Akhurst, Rosemary J (2009) Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res 11:202
Kang, Jong Seok; Saunier, Elise F; Akhurst, Rosemary J et al. (2008) The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nat Cell Biol 10:654-64